This bill establishes MED Grants for medical students who commit to 10 years of primary care practice, DENTAL Grants for dental students who commit to 10 years of rural practice, and NURSE Grants for nursing students. It authorizes $2.8 billion for medical school enrollment expansion (50% increase by year 2), $1.98 billion for nursing schools (30% increase by year 2), and $615 million for dental schools (20% increase by year 2) over fiscal years 2026-2035. The bill also allocates 5,022 additional Medicare residency positions annually (with 15% for psychiatry and 30% for primary care) and increases teaching health center funding with annual increases starting at $892.5 million in 2026. Additionally, it creates a $1.8 billion rural relocation grant program to help health care professionals move to rural areas with a 3-year commitment requirement.
The ALS Better Care Act amends Medicare to cover a specific set of ALS-related services - including specialized physician support, therapy, equipment coordination, and respiratory care - for patients diagnosed with ALS, starting January 1, 2027. Medicare will pay providers a single, annual amount per patient visit (beginning at $800 in 2027), adjusted yearly based on cost increases or recommendations from the Comptroller General. The bill also requires a report on challenges in funding and staffing ALS clinical trials to improve research progress. This addresses current low Medicare reimbursements that have caused long wait times and limited care access for ALS patients.
The Patients Deserve Price Tags Act requires hospitals, clinical diagnostic laboratories, imaging services providers, and ambulatory surgical centers to publicly disclose detailed pricing information for healthcare services in machine-readable formats. This includes standard charges, discounted cash prices, payer-specific negotiated rates, and other relevant pricing data that consumers can easily access and compare. The law applies to all facilities that provide services to Medicare beneficiaries, with implementation dates starting in 2026 for hospitals and 2027 for other providers. Non-compliant facilities face daily civil monetary penalties ranging from $300 to $10,000 per day, depending on facility size and duration of non-compliance.
This bill requires the Medicare program to audit prior authorization rules for high-cost items and drugs by 2027, identifying those needing excessive paperwork steps. By 2028, it mandates standardized prior authorization rules across all Medicare Advantage plans for these specific items and drugs. The law exempts providers in certain risk-based care models (like accountable care organizations) from these standardized requirements. It directly affects Medicare Advantage enrollees and plans by simplifying paperwork for certain treatments and medications. The bill aims to reduce administrative burdens for providers and patients without changing coverage decisions.
This bill (S 3688, RURAL Rate Act) increases Medicare reimbursement rates for healthcare providers in certain rural areas. It requires the Medicare program to set a minimum floor of 1.67 for practice expense and work geographic payment indices after January 1, 2026, if the standard calculation would produce a lower rate. This directly affects doctors and clinics in designated rural locations that currently receive lower Medicare payments due to geographic pricing. The change ensures these providers receive at least 1.67 times the standard rate for services, aiming to address historical underpayment. The policy applies to Medicare Part B payments for services furnished in qualifying rural areas starting in 2026.
This bill reinstates $200 transfer and manufacturing taxes on most firearms (replacing reduced rates from prior law) and maintains a $5 tax for "other weapons," affecting firearm manufacturers and dealers. It also adds $1.7 billion to the Medicare Part A trust fund for fiscal year 2026 to support hospital insurance costs. The tax changes apply 90 days after enactment, while the Medicare funding is available until expended. The bill directly impacts firearms industry costs and provides dedicated funding for Medicare's hospital insurance program.
This bill permanently extends the enhanced premium tax credit for Affordable Care Act marketplace insurance plans, directly affecting millions of lower-income households (earning 150%-400% of the federal poverty level) who purchase coverage through state or federal marketplaces. It establishes a sliding-scale percentage system where the tax credit reduces monthly premiums based on income, starting at 0% for households earning up to 150% of poverty and increasing to 8.5% for those earning 300%-400% of poverty. The bill replaces temporary provisions with permanent rules, ensuring consistent cost-sharing support for eligible buyers. The changes apply to tax years beginning after December 31, 2025.
The Medicare-X Choice Act of 2025 would establish a new public health insurance option called the "Medicare Exchange health plan" available through health insurance exchanges starting in 2028 for eligible individuals who are not enrolled in traditional Medicare. The plan would offer silver and gold coverage levels with no cost-sharing for primary care services, and would reimburse healthcare providers at Medicare rates. Healthcare providers enrolled in Medicare or Medicaid would be required to participate in this public plan, and the bill includes provisions to collect data addressing health disparities and improve care coordination. The plan would be funded through $1 billion in appropriations for each of two funds to establish and administer the program, while maintaining existing Medicare benefits and trust funds.
The Small Biotech Innovation Act exempts qualifying drugs from Medicare's drug price negotiation program starting in 2029 for small biotech manufacturers that meet specific R&D investment thresholds. To qualify, a company must have five or fewer single-source drugs and spend 30% to 70% of its net revenue on research and development (based on the number of drugs), while not being controlled by a foreign government. Manufacturers must apply annually with financial data and certification of R&D spending, and the exemption ends if the company is acquired by a non-qualifying entity after 2029. This directly affects small U.S.-based biotech firms developing innovative drugs, allowing them to avoid price negotiations under Medicare.
This bill increases federal Medicaid funding for states that expand spending on behavioral health services (mental health and substance use treatment). It creates a new 90% federal reimbursement rate for the *increase* in quarterly state spending on these services compared to the 2019 baseline, provided states use the funds to supplement existing state funding and improve service delivery (e.g., raising provider payment rates). States must report annually to Congress on payment rates, rationale, and service utilization for these programs. The policy directly affects all 50 states administering Medicaid and the providers delivering behavioral health services within those programs. The changes take effect January 1, 2025, following enactment.
